Abstract
Background/Aims: The aim of this study was to evaluate the relationship between plasma elimination of lidocaine and monoethylglycinexylidide (MEGX) formation, which is considered to be a quantitative liver function test. Methodology: The study included ten healthy subjects and 54 patients: 27 with chronic hepatitis and 27 with cirrhosis. Lidocaine and MEGX were measured at 0, 2, 5, 10, 15, 30 min and then every 30 min for 180 min using the TDX system. Results: In cirrhotic patients, the lidocaine half-life of the slow decline phase of the plasma disappearance curve (β-HL) and the lidocailze half-life of hepatic elimination from the second compartment (K20-HL) proved to be significantly abnormal, as did all parameters of MEGX formation. In chronic hepatitis, both the lidocaine kinetics and the MEGX formation parameters were within the normal range. In chronic hepatitis patients, MEGX formation (AUC 0-180) was significantly correlated to K20-HL (r(s) = -0.633, p <0.001) and to the rapid decline phase of the plasma disappearance curve (a-HL, r(s) = -0.483, p <0.05). In cirrhotic patients, MEGX was significantly correlated to K20-HL (r(s) = -0.423, p <0.05) and to β-HL (r(s) = -0.500, p <0.01). Conclusions: These results show that in chronic active hepatitis, MEGX formation from lidocaine is maintained as a metabolic process, whereas it is altered in cirrhotic patients. The interrelationship between lidocaine elimination and MEGX formation were somewhat different in the two liver diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 154-159 |
| Number of pages | 6 |
| Journal | Hepato-Gastroenterology |
| Volume | 45 |
| Issue number | 19 |
| Publication status | Published - 1998 |
Fingerprint
Keywords
- Chronic hepatitis
- Cirrhosis
- Lidocaine
- Monoethylglycinexylidide
ASJC Scopus subject areas
- Gastroenterology
Cite this
Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis. / Testa, Roberto; Campo, Nadia; Caglieris, Sergio; Risso, Domenico; Alvarez, Silvano; Arzani, Laura; Giannini, Edoardo; Lantieri, Pasquale Bruno; Celle, Guido.
In: Hepato-Gastroenterology, Vol. 45, No. 19, 1998, p. 154-159.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis
AU - Testa, Roberto
AU - Campo, Nadia
AU - Caglieris, Sergio
AU - Risso, Domenico
AU - Alvarez, Silvano
AU - Arzani, Laura
AU - Giannini, Edoardo
AU - Lantieri, Pasquale Bruno
AU - Celle, Guido
PY - 1998
Y1 - 1998
N2 - Background/Aims: The aim of this study was to evaluate the relationship between plasma elimination of lidocaine and monoethylglycinexylidide (MEGX) formation, which is considered to be a quantitative liver function test. Methodology: The study included ten healthy subjects and 54 patients: 27 with chronic hepatitis and 27 with cirrhosis. Lidocaine and MEGX were measured at 0, 2, 5, 10, 15, 30 min and then every 30 min for 180 min using the TDX system. Results: In cirrhotic patients, the lidocaine half-life of the slow decline phase of the plasma disappearance curve (β-HL) and the lidocailze half-life of hepatic elimination from the second compartment (K20-HL) proved to be significantly abnormal, as did all parameters of MEGX formation. In chronic hepatitis, both the lidocaine kinetics and the MEGX formation parameters were within the normal range. In chronic hepatitis patients, MEGX formation (AUC 0-180) was significantly correlated to K20-HL (r(s) = -0.633, p <0.001) and to the rapid decline phase of the plasma disappearance curve (a-HL, r(s) = -0.483, p <0.05). In cirrhotic patients, MEGX was significantly correlated to K20-HL (r(s) = -0.423, p <0.05) and to β-HL (r(s) = -0.500, p <0.01). Conclusions: These results show that in chronic active hepatitis, MEGX formation from lidocaine is maintained as a metabolic process, whereas it is altered in cirrhotic patients. The interrelationship between lidocaine elimination and MEGX formation were somewhat different in the two liver diseases.
AB - Background/Aims: The aim of this study was to evaluate the relationship between plasma elimination of lidocaine and monoethylglycinexylidide (MEGX) formation, which is considered to be a quantitative liver function test. Methodology: The study included ten healthy subjects and 54 patients: 27 with chronic hepatitis and 27 with cirrhosis. Lidocaine and MEGX were measured at 0, 2, 5, 10, 15, 30 min and then every 30 min for 180 min using the TDX system. Results: In cirrhotic patients, the lidocaine half-life of the slow decline phase of the plasma disappearance curve (β-HL) and the lidocailze half-life of hepatic elimination from the second compartment (K20-HL) proved to be significantly abnormal, as did all parameters of MEGX formation. In chronic hepatitis, both the lidocaine kinetics and the MEGX formation parameters were within the normal range. In chronic hepatitis patients, MEGX formation (AUC 0-180) was significantly correlated to K20-HL (r(s) = -0.633, p <0.001) and to the rapid decline phase of the plasma disappearance curve (a-HL, r(s) = -0.483, p <0.05). In cirrhotic patients, MEGX was significantly correlated to K20-HL (r(s) = -0.423, p <0.05) and to β-HL (r(s) = -0.500, p <0.01). Conclusions: These results show that in chronic active hepatitis, MEGX formation from lidocaine is maintained as a metabolic process, whereas it is altered in cirrhotic patients. The interrelationship between lidocaine elimination and MEGX formation were somewhat different in the two liver diseases.
KW - Chronic hepatitis
KW - Cirrhosis
KW - Lidocaine
KW - Monoethylglycinexylidide
UR - http://www.scopus.com/inward/record.url?scp=0031914116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031914116&partnerID=8YFLogxK
M3 - Article
C2 - 9496506
AN - SCOPUS:0031914116
VL - 45
SP - 154
EP - 159
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 19
ER -